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Abstract
Background: The objective of this clinical study was to assess the potential benefit of a dietary supplement, NP
06-1, on joint health in overweight and normal weight adults diagnosed with osteoarthritis.
Methods: An 8-week placebo-controlled, randomized, double-blind study was conducted with four groups
comparing the effects of NP 06-1 to placebo on overweight and normal weight subjects diagnosed with primary
osteoarthritis of the knee. NP 06-1 (a combination of two botanical extracts; Phellodendron amurense bark and
Citrus sinensis peel) or matching placebo were given in a dose of two capsules (370 mg each) twice daily. The
outcome measures were the Lequesne Algofunctional Index (LAI) for joint pain and movement as well as
biomarkers of inflammation (C-reactive protein [CRP] and erythrocyte sedimentation rate [ESR]).
Results: Eighty (80) subjects were enrolled and 45 subjects completed the study. No serious adverse events were
reported. The mean total LAI scores at baseline for the four groups ranged from 11.4 to 12.4 (SD 1.2 to 2.4).
Treatment for 8 weeks resulted in a statistical improvement in the LAI score in the overweight treatment group
compared to placebo (6.3 ± 2.3 vs 11.8 ± 1.5; p < 0.0001). At 8 weeks, a similar result was observed in the normal
weight groups (7.7 ± 1.4 vs 9.9 ± 0.9; p < 0.0001). There was a reduction in CRP levels with treatment in the
overweight treatment group at 8 weeks (-0.62 ± 0.2; 49%) compared to baseline (p < 0.001) and to placebo (p <
0.001). For the normal weight participants, there were significant reductions in CRP compared to baseline, but
not to the matched placebo group. Both overweight and normal weight treatment groups lost a significant amount
of weight compared to their placebo groups. The overweight treatment group lost an average of 5% body weight
after 8 weeks. There was no significant change in ESR in any of the groups.
Conclusion: In this pilot study, NP 06-1 had beneficial effects on symptoms of osteoarthritis of the knee as
measured using LAI scores and had anti-inflammatory effects as measured using CRP. Administration of NP 06-1
was also associated with weight loss, which may have been a contributing factor to the other benefits.
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Background
Osteoarthritis, the most common form of arthritis, is
characterized by degradation of articular cartilage, which
manifests as joint pain and reduced mobility. The origin
of the disease is unknown but obesity, joint injury, meta-
bolic diseases, bone and joint malfunctions, genetic fac-
tors and age have been implicated. Therapies for
osteoarthritis include weight control, physiotherapy and
pharmacological agents. Conventional drug treatments
include analgesics, anti-inflammatory agents, disease
modifying therapies, hyaluronic acid, intra-articular glu-
cocorticoids and topical analgesic/anti-inflammatory
agents [1]. More recently there has been a focus on nutri-
tional support. Recent systematic reviews highlight the
scientific evidence for potential nutritional and herbal
preparations for those with osteoarthritis [2,3].
The subject of this study, NP 06-1 (Citrofen®, Next Phar-
maceuticals, Salinas, CA), is a proprietary product consist-
ing of a blend of extracts of Phellodendron amurense tree
bark and Citrus sinensis (orange) peel standardized to ber-
berine and polymethoxylated flavones, respectively.
Next Pharmaceuticals has previously conducted bioassay
guided research on Phellodendron amurense tree bark
resulting in a proprietary extract that has demonstrated
analgesic and anti-inflammatory activity both in vitro and
in vivo, in unpublished studies. Following this research, a
product was developed (Nexrutine®) that provided relief
from pain and/or inflammation associated with over-
exertion (i.e. sore muscles, sore joints, stiff joints) and
osteoarthritis of the knee in unpublished open-label clin-
ical studies.
Citrus sinensis (orange) peel extracts contain bioflavo-
noids, including polymethoxylated flavones (PMFs). The
latter compounds are known to be anti-inflammatory and
to have antioxidant and hypolipidemic effects [4-6]. Next
Pharmaceuticals has licensed US Patent Nos. 6,184,246
and 6,987,125 obtained by the USDA for actions
described by PMFs.
NP 06-1 was formulated with the goal of combining the
beneficial effects of both the phellodendron and orange
peel extracts. The primary objective of this clinical study
was to study the safety and efficacy of NP 06-1 in the man-
agement of joint pain and mobility caused by osteoarthri-
tis of the knee. Secondary objectives were to study the
effects on biomarkers related to inflammation. Both over-
weight and normal weight subjects were studied to deter-
mine whether or not there might be a difference in
benefits to these two groups. A portion of this clinical
study that examined the potential benefits from NP 06-1
on cardiovascular health has recently been published [7].
The published data showed that NP 06-1 had a favorable
effect on lipid levels: lowering plasma triglycerides and
LDL-cholesterol, as well as increasing HDL-cholesterol
levels. NP 06-1 also had a favorable effect on blood pres-
sure and fasting glucose levels (the latter only in the over-
weight group).
Methods
Study Design
The study was a placebo-controlled, randomized, double-
blind study with four groups. Forty overweight and forty
normal weight subjects were enrolled into either treat-
ment or placebo groups, with twenty subjects in each
group as shown in Table 1. Subjects were recruited via
advertisements at the University of Yaounde I Teaching
Hospital, the Djongolo Baptist Hospital and through the
public media. The IRB of the Faculty of Medicine and Bio-
medical Sciences of the University of Yaounde in Cam-
eroon approved the study and all subjects signed an
informed consent. Dr. Julius Oben, Associate Professor of
Nutritional Biochemistry at the University of Yaounde I,
Cameroon was the principal investigator.
To be included in the study, participants needed to be
adult men and women, 25 to 60 years of age, diagnosed
with primary osteoarthritis of the target knee using the
American College of Rheumatology guidelines [8] by the
treating physician and confirmed by the clinical investiga-
tor, and with a BMI between 25 kg/m2 to 40 kg/m2 (over-
Table 1: Study Groups.
Group # BMI Category Treatment Enrollment (Completed)
OP Overweight* Placebo 20 (13)
OT Overweight* Active 20 (14)
NP Normal weight† Placebo 20 (7)
NT Normal weight † Active 20 (11)
*BMI 25 kg/m2 – 40 kg/m2 †BMI 18.9 kg/m2 – 24.9 kg/m2
The number of subjects initially enrolled is listed; with the number that completed the study in parenthesis.Nutrition Journal 2009, 8:38 http://www.nutritionj.com/content/8/1/38
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weight groups) or 18.9 kg/m2 to 24.9 kg/m2 (normal
weight groups).
The exclusion criteria were: morbid obesity BMI > 40 kg/
m2, diagnosis of rheumatoid arthritis, joint replacement
in either knee, unable to walk without assistance, enroll-
ment in another clinical study in the past 6 months, preg-
nancy, active infection, autoimmune disease, AIDS, HIV,
active hepatitis, active malignancy, and diabetes requiring
daily insulin management.
Subjects were instructed to avoid taking analgesics for a 5
day period prior to enrollment and during the study. Sub-
jects were also instructed to stay with their normal exercise
and diet regimens.
Study Products and Administration
NP 06-1 is a proprietary product of Next Pharmaceuticals,
Salinas, California. It is a blend of Phellodendron amurense
(Rupr.) [Rutaceae] tree bark extract standardized to a min-
imum of 50% berberine and Citrus sinensis (L.) Osbeck
[Rutaceae] peel extract standardized to a minimum of
30% polymethoxylated flavones (PMF). Berberine and
PMFs were chosen as representative chemical constituents
because they have demonstrated biological activity. Next
Pharmaceuticals has licensed US Patent Nos. 6,184,246
and 6,987,125 obtained by the USDA for biological activ-
ity of PMFs.
Subjects were allocated into groups using a random
number table and instructed to take two NP 06-1 capsules
(370 mg formula per capsule) or matching placebo (iden-
tical red two-piece hard shell capsules) with food in the
morning and at night (4 capsules per day) for a total of 8
weeks.
Study Variables
The study variables were: physical pain and joint move-
ment as measured by the total score on the standardized
LAI questionnaire [9], as well as biomarkers for inflamma-
tion: CRP and ESR. The LAI scale (algofunctional indices)
is a validated instrument for evaluating therapies for oste-
oarthritis. The LAI score is the sum of the responses to 10
questions regarding pain/discomfort, maximum distance
walked and activities of daily living. The subjects were
asked to respond to each question using a 5 point Likert
scale (0, 0.5, 1.0, 1.5 or 2.0; where 0 is without and 2 is
with difficulty/discomfort). The LAI questionnaire was
completed by each subject at baseline, at 4 weeks and at 8
weeks. Blood samples (8 ml) were collected by venous
puncture at times 0, 4 and 8 weeks. Subjects were
requested to come to the study center on the mornings of
each site visit after a 12-hour fast. CRP was measured
using the Dade Turbitimer. ESR was measured using the
Westergren method. Body weight was determined in 12-
hour fasted subjects using a Tanita™ scale and height was
measured using a stadiometer.
Safety Assessment
Subjects were given three emergency telephone numbers
to contact during the conduct of the study, if they had any
adverse events or other concerns related to the study. Each
subject was interviewed during site visits to solicit infor-
mation on possible adverse effects they might have
encountered. Participants were instructed to inform the
investigator, if the reason for dropping out of the study
was due to adverse effects.
Statistical Analysis
Data were analyzed using SAS version 9.2 (SAS Institute,
1999). Descriptive statistics were run for each group (Pla-
cebo and NP 06-1) and each time point (baseline, 4 weeks
and 8 weeks). Initially, an analysis of variance model was
used to determine whether or not the groups and times
differed in baseline scores. No differences were found. An
analysis of variance model, with repeated measures, was
used to compare changes of physiological measures over
the trial period and between groups. First, we examined
models with all 2-way and 3-way interactions. Since the 3-
way interactions were found significant, we examined
each weight group separately. For each weight group, we
used an analysis of variance model with treatment (Pla-
cebo vs and NP 06-1) as a fixed effect and time (4 weeks
vs 8 weeks) as a repeated measure to determine the effects
of NP 06-1.
Results
Eighty (80) subjects were enrolled in the study and rand-
omized into four groups designated OP (Overweight/Pla-
cebo), OT (Overweight/Treatment), NP (Normal weight/
Placebo) and NT (Normal weight/Treatment) (Table 1).
Forty five (45) subjects completed the study and the rea-
sons given by the dropouts are given in Table 2. The drop-
outs were fairly evenly distributed among the groups, with
the exception of Group NP which lost nearly twice as
many participants as the other groups. The majority of
Group NP dropouts cited no improvement in their condi-
tion as their reason for dropping out. There is no indica-
tion that their demographics were different from those
who stayed in the study. No serious adverse events were
reported by any of the dropouts or by those who com-
pleted the study. The following results were compiled
using data from those who completed the study.
LAI Scores
The mean total LAI scores at baseline for the four groups
ranged from 11.4 to 12.4 (standard deviations 1.2 to 2.4)
with no statistical differences between them (p = 0.43)
(Table 3). Comparison of the overweight groups (OT vs.
OP) showed a significant decrease in LAI scores in theNutrition Journal 2009, 8:38 http://www.nutritionj.com/content/8/1/38
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treatment group compared to the placebo at 4 weeks (8.2
± 2.7 vs 11.7 ± 1.7) and at 8 weeks (6.3 ± 2.3 vs 11.8 ± 1.5)
(both p < 0.0001) (Table 4). For Group OT, there were sta-
tistically significant decreases in LAI scores at 4 weeks (-
3.5 ± 2.2) and 8 weeks (-5.4 ± 2.2) compared to baseline
(both p < 0.0001) (Table 3). There was also a difference
between the 4 and 8 week time periods (p = 0.002). In
contrast there were no statistically significant changes
from baseline for Group OP.
Comparison of normal weight groups (NT vs. NP) also
showed a significant decrease in LAI scores in the treat-
ment compared to the placebo group at 4 weeks (7.6 ± 1.9
vs 10.3 ± 1.5) and 8 weeks (7.7 ± 1.4 vs 9.9 ± 0.9 (both p
< 0.0001). For Group NT there were statistically signifi-
cant decreases in LAI scores compared to baseline at 4
weeks (-3.7 ± 2.1) and 8 weeks (-3.7 ± 1.7) (both p <
0.0001). There was also a difference between the 4 and 8
week time periods (p = 0.012). For Group NP there were
significant differences between baseline and 4 weeks (-1.4
± 2.8; p = 0.019) and between baseline and 8 weeks (-1.9
± 2.1; p < 0.0001). No significant difference was found
between the 4 and 8 week time periods.
Multivariate analysis showed a treatment effect for NP 06-
1 in both the overweight and normal weight groups (p <
Table 2: Reasons given by Subjects for dropping out of the Study.
Group # Number of Subjects Reason for drop out
OP 2 Reported no improvement in their condition
1 Nausea and vomiting; Malaria attack
1 Moved out of town
3 No reason given
OT 1 Reported improvement as too slow
1 Tested positive for hepatitis
1 Moved out of town
3 No reason given
NP 7 Reported no improvement in their condition
1N a u s e a
1 Started weight management program
1 Started fasting and stopped treatment
3 No reason given
NT 1 Malaria attack
1N a u s e a
1 Started fasting and stopped treatment
6 No reason givenNutrition Journal 2009, 8:38 http://www.nutritionj.com/content/8/1/38
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0.0001 and 0.003, respectively), with no difference in the
effect between the overweight and normal weight groups
(weight by treatment interaction).
Biomarkers of Inflammation
The mean total CRP measurements at baseline for the four
groups ranged from 0.8 to 1.3 mg/L (Table 5). There were
no significant differences between the groups at baseline.
Comparison of overweight groups showed a significant
difference in CRP between OT and OP groups at 4 and 8
weeks (p < 0.05 and p < 0.001, respectively). For Group
OT, there were significant decreases in CRP at 4 weeks (-
0.35 ± 0.2; 28%) and 8 weeks (-0.62 ± 0.2; 49%) com-
pared to baseline (both p < 0.001). There were smaller,
but significant, changes from baseline for Group OP.
Comparison of normal weight groups showed no signifi-
cant differences in CRP between treatment and placebo.
For Group NT there were significant decreases in CRP over
time; at 4 weeks (-0.31 ± 0.2; 27%) and 8 weeks (-0.51 ±
0.2; 44%) compared to baseline (both p < 0.001). In con-
trast there were no significant changes from baseline for
Group NP. There were no significant changes in ESR in
any of the groups (Table 5).
Weight/BMI
In Group OT, the subjects lost a significant amount of
weight and their BMI was reduced compared to the start
of the study (p < 0.001 at 4 and 8 weeks) (Table 6). They
lost an average of 2.5 kg (5.5 pounds, 3.1% of body
weight) after 4 weeks and an average of 4.2 kg (9.2
pounds, 5.1% of body weight) after 8 weeks. There were
smaller, but significant, changes in weight and BMI from
baseline for Group OP. Comparisons of weight loss
between overweight groups revealed that the treatment
group lost on average 3.7 times as much weight as the pla-
cebo group at 8 weeks (9.2 pounds versus 2.5 pounds) (p
< 0.001). However, in comparison, the changes in BMI
between the two overweight groups were not significant.
In Group NT there was a significant decrease in weight
and BMI at 8 weeks (p < 0.05) compared to baseline. At 8
weeks, this group lost an average of 1.18 kg (2.6 pounds,
1.8% of body weight). Group NP also had a significant
loss of weight and BMI after 8 weeks compared to the start
of the study (p < 0.01). Comparisons of weight loss
between normal weight groups revealed that the treat-
ment group lost on average 1.5 times as much weight as
the placebo group at 8 weeks (2.6 pounds versus 1.7
pounds) (p < 0.01). There was no significant difference in
change in BMI between the normal weight treatment and
placebo groups.
Discussion
LAI scores (algofunctional indices) have been validated
for use in assessing the severity of osteoarthritis of the hip
and knee [9]. LAI scores, which incorporate points for
Table 3: LAI data.
Group Baseline 4 weeks 8 weeks Δ 0–4 wks Δ 0–8 wks
OP 12.4 ± 1.3 11.7 ± 1.7 11.8 ± 1.5 -0.7 ± 1.6 -0.6 ± 1.7
OT 11.7 ± 1.5 8.2 ± 2.7 6.3 ± 2.3 -3.5 ± 2.2* -5.4 ± 2.2*
NP 11.7 ± 2.4 10.3 ± 1.5 9.9 ± 0.9 -1.4 ± 2.8* -1.9 ± 2.1*
NT 11.4 ± 1.2 7.6 ± 1.9 7.7 ± 1.4 -3.7 ± 2.1* -3.7 ± 1.7*
Values at baseline, 4 weeks and 8 weeks are listed as means ± standard deviation. Mean changes (Δ) ± standard deviation after 4 weeks and 8 weeks 
compared to baseline are listed in the last two columns. A negative value indicates a decrease in value. Values* are significant comparisons (<0.05) 
based on analysis of variance model results comparing changes from baseline to 4 weeks or 8 weeks. Groups are as follows: OP = overweight/
placebo, OT = overweight/treatment, NP = normal weight/placebo and NT = normal weight/treatment.
Table 4: Inter-Group Analysis Comparing the Paired Treatment 
to PlaceboGroups.
Group OP vs. Group 0T Group NP vs. Group NT
4 weeks 8 weeks 4 weeks 8 weeks
LAI <0.0001 <0.0001 <0.0001 <0.0001
CRP <0.05 <0.001 NS NS
ESR NS NS <0.05 NS
Weight <0.01 <0.001 <0.05 <0.01
BMI NS NS NS NS
Based on analysis of variance F-statistics, P-values are for comparisons 
between overweight placebo (OP) and overweight treatment (OT) 
groups and between normal weight placebo (NP) and normal weight 
treatment (NT) groups at 4 and 8 weeks. NS = not significant.Nutrition Journal 2009, 8:38 http://www.nutritionj.com/content/8/1/38
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pain, maximum distance walked and activities of daily liv-
ing, typically range from 1 to 14. Scores of 1 to 4 indicate
a minor handicap while a score of 14 indicates an
extremely severe handicap. Clinical studies used to assess
the potential benefits of drugs on osteoarthritis typically
start with subjects who have scores of 9 to 11 (SD 2.3 to
3.8). Upon administration of non-steroidal anti-inflam-
matory drugs (NSAIDS) for one or two weeks, those scores
usually decrease by 2.5 to 4 points: decreases of approxi-
mately 25 to 40%. In this study, the groups had mean
scores within the range of 11 to 13 (SD 1.2 to 2.4) at base-
line, which indicates a very severe handicap from osteoar-
thritis of the knee. After 8 weeks there was a decrease of
3.7 ± 2.1 points in the normal weight treatment group and
a decrease of 5.4 ± 2.2 points in the overweight treatment
group. The degree of improvement observed with NP 06-
1 is comparable to that reported for NSAIDS.
CRP is an acute phase protein that is produced by the liver
during an inflammatory reaction. Serum CRP levels are
often higher in those with osteoarthritis and are associ-
ated with joint pain, as well as the severity and progres-
sion of the disease [10,11]. Recent studies have indicated
that the correlation between CRP levels and osteoarthritis
involves other variables besides the disease state [12].
Body weight has been determined to influence CRP levels
due to mechanical effects, as well as the production of
inflammatory mediators by adipocytes. A systematic
review of the literature covering weight reduction in obese
subjects diagnosed with osteoarthritis of the knee con-
cluded that the disability associated with the disease could
be significantly improved with a loss of over 5.1% body
weight [13]. In contrast with the improvement in disabil-
ity, loss of body weight did not necessarily predict relief
from pain. Another systematic review reported that weight
loss in the general adult population is associated with
reductions in CRP levels. This analysis concluded that for
each 1 kg of weight loss, the mean change in CRP level was
decreased by 0.13 mg/L (weighted Pearson correlation, r =
0.85) [14]. A study investigating the correlation between
CRP and osteoarthritic disease progression found that
subjects with inflammatory infiltrates within the synovial
membrane had a mean CRP level of 4.7 ± 5.0 mg/L, while
those without infiltrates had a mean CRP level of 1.7 ± 3.6
[11].
Table 5: Markers of Inflammation: CRP & ESR.
Group
Variable
Baseline 4 weeks 8 weeks Δ 0–4 wks Δ 0–8 wks
OP
CRP (mg/L) 1.19 ± 0.26 1.02 ± 0.27 1.08 ± 0.25 -0.17 ± 0.2* -0.11 ± 0.07*
ESR (mm/h) 13.6 ± 2.5 13.5 ± 2.0 13.6 ± 1.7 -0.10 ± 2.4 0.0 ± 2.4
OT
CRP (mg/L) 1.33 ± 0.20 0.95 ± 0.11 0.68 ± 0.14 -0.35 ± 0.2* -0.62 ± 0.2*
ESR (mm/h) 12.7 ± 0.9 13.0 ± 2.1 12.9 ± 1.6 0.31 ± 2.4 0.38 ± 1.8
NP
CRP (mg/L) 0.76 ± 0.19 0.76 ± 0.19 0.68 ± 0.18 0.04 ± 0.1 -0.08 ± 0.1
ESR (mm/h) 12.5 ± 1.4 12.8 ± 1.7 12.8 ± 1.3 0.30 ± 1.0 0.30 ± 1.1
NT
CRP (mg/L) 1.15 ± 0.22 0.84 ± 0.13 0.64 ± 0.50 -0.31 ± 0.2* -0.51 ± 0.2*
ESR (mm/h) 13.1 ± 1.2 13.5 ± 1.7 13.3 ± 0.9 0.36 ± 2.5 0.18 ± 1.3
Values at baseline, 4 weeks and 8 weeks are listed as means ± standard deviation. Mean changes (Δ) ± standard deviation after 4 weeks and 8 weeks 
compared to baseline are listed in the last two columns. A negative value indicates a decrease in value and a positive number represents an increase 
in value. Values* are significant comparisons (<0.05) based on analysis of variance model results comparing changes from baseline to 4 weeks or 8 
weeks. Groups are as follows: OP = overweight/placebo, OT = overweight/treatment, NP = normal weight/placebo and NT = normal weight/
treatment.Nutrition Journal 2009, 8:38 http://www.nutritionj.com/content/8/1/38
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In the present study, the mean levels of CRP at baseline for
the four groups ranging from 0.76 to 1.3 mg/L indicated a
relatively low level of inflammation. In spite of this, there
was a reduction in CRP for the overweight participants
with treatment compared to placebo. There was no com-
parative treatment effect for the normal weight partici-
pants. However there was an effect of treatment over time
for both the overweight and normal weight groups. The
overweight treatment group experienced a weight loss of
5.1% after 8 weeks. The normal weight subjects also lost
body weight, but to a lesser degree. It appears from current
literature, that the decreases in CRP in this study may have
been influenced by loss in body weight [13,14]. Also the
reduction in weight may have had an influence in the
reduction in LAI scores [13].
NP 06-1 contains standardized amounts of berberine, a
constituent of the Phellodendron extract, and PMFs from
citrus. Both of these components have demonstrated anti-
inflammatory activity. Plant extracts containing berberine
have traditionally been used in rheumatic and other
chronic inflammatory diseases [15]. In support of the tra-
ditional use, extracts containing berberine have demon-
strated anti-inflammatory activity in animal models
[16,17]. In vitro studies indicate that berberine inhibits
the production of inflammatory mediators prostaglandin
E2 and interleukin (IL)-12 [18,19]. Berberine also reduced
the levels of expression of mRNA for pro-inflammatory
cytokines including tumor necrosis factor (TNF)-alpha,
IL-6, CRP and haptoglobin [20].
Berberine has also been shown to reduce body weight in
mice and rats [21]. Histological studies indicated that ber-
berine reduced adipocyte size but not cell number. Meas-
urements of metabolic gene expression in adipose and
muscle tissue indicated that berberine up regulated genes
involved in energy expenditure and down regulated the
expression of genes involved in lipogenesis. In vitro stud-
ies determined that berberine increased AMP-activated
protein kinase (AMPK) activity in 3T3-L1 adipocytes and
L6 myotubes, as well as reduced lipid accumulation in
3T3-L1 cells. In addition, berberine reduced secretion of
leptin, which regulates appetite and energy metabolism,
from 3T3-L1 adipocytes.
Citrus PMFs have been reported to exhibit anti-inflamma-
tory activity in vivo and in vitro. PMFs regulated levels of
adipocytokines through suppression of TNF-alpha, inter-
Table 6: Body Weight, BMI.
Group Baseline 4 weeks 8 weeks Δ 0–4 wks Δ 0–8 wks
OP
Weight (kg) 85.0 ± 12.7 83.9 ± 12.6 83.8 ± 12.2 -1.1 ± 0.96* -1.2 ± 1.3*
BMI (kg/m2) 31.1 ± 4.2 30.7 ± 4.2 30.7 ± 4.1 -0.4 ± 0.59* -0.4 ± 0.32*
OT
Weight (kg) 81.7 ± 9.3 79.2 ± 9.1 77.5 ± 8.3 -2.5 ± 1.09* -4.2 ± 1.24*
BMI (kg/m2) 31.1 ± 3.7 30.2 ± 3.7 29.5 ± 3.4 -0.9 ± 0.11* -1.6 ± 0.11*
NP
Weight (kg) 67.1 ± 3.6 66.8 ± 3.8 66.5 ± 3.8 -0.3 ± 0.60 -0.6 ± 0.34*
BMI (kg/m2) 24.0 ± 1.6 23.9 ± 1.6 23.8 ± 1.6 -0.1 ± 0.05 -0.2 ± 0.04*
NT
Weight (kg) 67.0 ± 9.7 66.5 ± 8.9 65.8 ± 8.7 -0.5 ± 1.08 -1.2 ± 1.3*
BMI (kg/m2) 24.8 ± 2.6 24.7 ± 2.3 24.4 ± 2.3 -0.1 ± 0.05 -0.4 ± 0.08*
Values at baseline, 4 weeks and 8 weeks are listed as means ± standard deviation. Mean changes (Δ) ± standard deviation after 4 weeks and 8 weeks 
compared to baseline are listed in the last two columns. A negative value indicates a decrease in value and a positive number represents an increase 
in value. Values* are significant comparisons (<0.05) based on analysis of variance model results comparing changes from baseline to 4 weeks or 8 
weeks. Groups are as follows: OP = overweight/placebo, OT = overweight/treatment, NP = normal weight/placebo and NT = normal weight/
treatment.Nutrition Journal 2009, 8:38 http://www.nutritionj.com/content/8/1/38
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feron-gamma, IL-1 beta and IL-6 expression [22]. PMFs
also suppressed TNF-alpha expression by monocytes, per-
haps due to inhibition of phosphodiesterase activity [23].
This pilot study has a number of weaknesses. The most
obvious weakness is the number of dropouts. There was
no clear evidence of difference or bias in the demograph-
ics of the dropouts compared to those who stayed in the
study; however, there was insufficient information to run
an analysis of the two groups. Care must be taken with
respect to dropouts when a full blown study is conducted.
We also acknowledge that we have no information on
patient compliance with treatment protocol.
In summary, it appears from the results of this pilot study
that NP 06-1 may benefit subjects with osteoarthritis of
the knee through an anti-inflammatory action as well as
through a loss of body weight. In addition to increased
osteoarthritis-related disability, obesity is correlated with
an array of conditions associated with a high risk of diabe-
tes, hypertension and/or cardiovascular disease called
metabolic syndrome [24]. Symptoms of metabolic syn-
drome include abdominal obesity, dyslipidemia and ele-
vated blood pressure and insulin resistance.
We have previously reported that administration of NP
06-1 is associated with a general improvement in lipid lev-
els, with reductions in triglycerides and low-density lipo-
protein (LDL)-cholesterol and an increase in high-density
lipoprotein (HDL)-cholesterol [7]. In that same report, we
also reported treatment-related decreases in blood pres-
sure and a decrease in fasting glucose levels in an over-
weight population. Thus additional studies are indicated
to explore the use of NP 06-1 for osteoarthritis and for
metabolic syndrome.
Conclusion
NP 06-1 has been shown in a placebo-controlled, rand-
omized, double-blind pilot clinical study to offer several
potential health benefits in normal and overweight sub-
jects with osteoarthritis of the knee. These potential bene-
fits include improvement of knee joint pain/flexibility as
measured by the LAI scores and a reduction in inflamma-
tion as measured using CRP levels. Treatment-induced
weight loss may have been a contributing factor to these
improvements. NP 06-1 was administered to the trial par-
ticipants in a dose of 4 capsules (1,480 mg) per day for 8
weeks without significant adverse events.
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